Publication: Platinum-induced neurotoxicity: A review of possible mechanisms
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Ertaş, Hülya | |
dc.contributor.buuauthor | Caner, Burcu | |
dc.contributor.buuauthor | CANER, BURCU | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/OnkolojiAnabilim Dalı. | |
dc.contributor.orcid | 0000-0002-5872-8825 | |
dc.contributor.researcherid | HJH-6371-2023 | |
dc.contributor.researcherid | AAE-8549-2022 | |
dc.date.accessioned | 2024-10-14T10:46:24Z | |
dc.date.available | 2024-10-14T10:46:24Z | |
dc.date.issued | 2017-08-10 | |
dc.description.abstract | Patients treated with platinum-based chemotherapy frequently experience neurotoxic symptoms, which may lead to premature discontinuation of therapy. Despite discontinuation of platinum drugs, these symptoms can persist over a long period of time. Cisplatin and oxaliplatin, among all platinum drugs, have significant neurotoxic potential. A distal dose-dependent symmetrical sensory neuropathy is the most common presentation of platinum neurotoxicity. DNA damage-induced apoptosis of dorsal root ganglion (DRG) neurons seems to be the principal cause of neurological symptoms. However, DRG injury alone cannot explain some unique symptoms such as cold-aggravated burning pain affecting distal extremities that is observed with oxaliplatin administration. In this article, we briefly reviewed potential mechanisms for the development of platinum drugs-associated neurological manifestations. | |
dc.identifier.doi | 10.5306/wjco.v8.i4.329 | |
dc.identifier.endpage | 335 | |
dc.identifier.issn | 2218-4333 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 329 | |
dc.identifier.uri | https://doi.org/10.5306/wjco.v8.i4.329 | |
dc.identifier.uri | https://hdl.handle.net/11452/46355 | |
dc.identifier.volume | 8 | |
dc.identifier.wos | 000415576700003 | |
dc.indexed.wos | WOS.ESCI | |
dc.language.iso | en | |
dc.publisher | Baishideng Publishing Group Inc | |
dc.relation.journal | World Journal Of Clinical Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Root ganglion neurons | |
dc.subject | Oxaliplatin-induced neurotoxicity | |
dc.subject | Induced peripheral neurotoxicity | |
dc.subject | Nerve hyperexcitability | |
dc.subject | Anticancer drug | |
dc.subject | Up-regulation | |
dc.subject | In-vitro | |
dc.subject | Cisplatin | |
dc.subject | Neuropathy | |
dc.subject | Dna | |
dc.subject | Cisplatin | |
dc.subject | Dorsal root ganglion | |
dc.subject | Mechanism | |
dc.subject | Oxaliplatin | |
dc.subject | Neurotoxicity | |
dc.subject | Neuropathic pain | |
dc.subject | Sodium channel | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.title | Platinum-induced neurotoxicity: A review of possible mechanisms | |
dc.type | Review | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 9807c94e-65ab-4632-b31b-dc9b1db15d7d | |
relation.isAuthorOfPublication.latestForDiscovery | 9807c94e-65ab-4632-b31b-dc9b1db15d7d |
Files
Original bundle
1 - 1 of 1